TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris (ALTME)and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa).
TME Pharma develops drugs using technology yielding L -RNA molecules, which are of mirror-image configuration compared to naturally occurring D -RNA molecules. The company calls these agents Spiegelmers,[2][3] from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes.[4]
Products
Some Spiegelmer candidates were in clinical trials.
A Spiegelmer (NOX-A12, olaptesed pegol) was under development as a combination therapy for a number of cancer indications. NOX-A12 targets CXCL12 (C-X-C Chemokine Ligand 12), a key chemokine protein. Favorable results were reported in October 2018 during the 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York, NY, USA.[5][6][7][8]
A different Spiegelmer (NOX-E36, emapticap pegol) was tested for the treatment of progressive diabetic nephropathy.[9] Favorable results were reported in June 2014 in a company press release.[10] NOX-E36 targets MCP-1, also called CCL2.[4] A third Spiegelmer (NOX-H94, lexaptepid pegol) was in a clinical trial for the treatment of anemia of chronic disease.[11][12]
References
- Investors. Noxxon.com. Retrieved on 2018-02-14.^
- Vater A, Klussmann S. Toward third-generation aptamers: Spiegelmers and their therapeutic prospects Curr Opin Drug Discov Dev, March 2003^
- Spiegelmers for Therapeutic Applications WILEY-VCH, 2006^
- News Review: Aram Mangasarian, Noxxon Pharma AG pharmatelevision.com, retrieved 2013-07-16^
- {{ClinicalTrialsGov|NCT03168139|Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer}}^
- {{ClinicalTrialsGov|NCT01521533|NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma}}^
- {{ClinicalTrialsGov|NCT01486797|NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia}}^
- Noxxon Presents Top-Line Data from Nox-A12 Monotherapy Part of Ongoing Metastatic Colorectal and Pancreatic Cancer Trial Noxxon, October 2, 2018^
- {{ClinicalTrialsGov|NCT01547897|NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria}}^
- Noxxon's Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference Noxxon, June 2, 2014^
- {{ClinicalTrialsGov|NCT01691040|Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer}}^
- The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys Blood, March 2013^